Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily 20 Year Treasury Bull 3X Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.9 (market cap $2.03B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TMF | XBI | |
|---|---|---|
Market Cap | $2.03B | $10.11B |
Volume | 12,241,664 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $44.14 | $169.55 |
52-Week Low | $25.19 | $104.99 |
Typical Hold Time | 28 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMF trades at $25.23, down 0.51% with bearish technical signals from moving averages. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest. Key support sits at $24-25 while resistance levels are at $25-26. RSI readings below 20 suggest potential oversold conditions despite the bearish trend.
As a leveraged Treasury ETF, TMF faces interest rate sensitivity and market volatility risks. The bearish technical outlook and Federal Reserve policy uncertainty create headwinds, though oversold conditions may present tactical opportunities for investors anticipating rate cuts.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
